Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: Recurrence score alone and integrated with pathologic and clinical factors

Journal of Clinical Oncology

Volumn 29, Issue 33, 2011, Pages 4365-4372

  Tang, Gong ^a,b   Cuzick, Jack ^d   Costantino, Joseph P ^a,b   Dowsett, Mitch ^e   Forbes, John F ^f   Crager, Michael ^g   Mamounas, Eleftherios P ^a,h   Shak, Steven ^g   Wolmark, Norman ^a,c  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f UNIVERSITY OF NEWCASTLE   (Australia)

^g Genomic Health   (United States)

^h Aultman Health Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; NODE NEGATIVE BREAST CANCER; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCORING SYSTEM; TRANSLATIONAL RESEARCH;

EID: 81755161593     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.3714     Document Type: Article

References (20)

1. Harris L, Fritsche H, Mennel R, et al.: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007 (Pubitemid 350232263)
2. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, Breast Cancer (version 2.2008). http://www.nccn. org
3. Ravdin PM, Siminoff LA, Davis GJ, et al.: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001 (Pubitemid 32176272)
4. Paik S, Shak S, Tang G, et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004 (Pubitemid 40051905)
5. Paik S, Tang G, Shak S, et al.: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006 (Pubitemid 46622311)
6. Habel LA, Shak S, Jacobs MK, et al.: A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8:R25, 2006
7. Goldstein LJ, Gray R, Badve S, et al.: Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063-4071, 2008
8. Albain KS, Barlow WE, Shak S, et al.: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 11:55-65, 2010
9. Dowsett M, Cuzick J, Wale C, et al.: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 28:1829-1834, 2010
10. Bryant J: Toward a more rational selection of tailored adjuvant therapy: Data from the National Surgical Adjuvant Breast and Bowel Project. Ninth International St. Gallen Breast Cancer Conference, St. Gallen, Switzerland, January 26-29, 2005
11. Paik S, Shak S, Tang G, et al.: Risk classification of breast cancer patients by the Recurrence Score assay: Comparison to guidelines based on patient age, tumor size, and tumor grade. Twenty-Seventh Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2004 (abstr 104)
12. Fisher B, Costantino J, Redmond C, et al.: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989 (Pubitemid 19062522)
13. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
14. Royston P, Parmar MKB: Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modeling and estimation of treatment effects. Stat Med 21:2175-2197, 2002 (Pubitemid 34830755)
15. Breslow NE: Contribution to the discussion on the paper by DR Cox, Regression and life tables. J R Stat Soc B 34:216-217,1972
16. Bura E, Gastwirth JL: The binary regression quantile plot: Assessing the importance of predictors in binary regression visually. Biom J 43:5-21, 2001
17. Huang Y, Pepe MS, Feng Z: Evaluating the predictiveness of a continuous marker. Biometrics 63:1181-1188, 2007 (Pubitemid 350212578)
18. Paule RC, Mandel J: Consensus values and weighting factors. J Res Natl Bur Stand 87:377-385, 1982
19. DerSimonian R, Kacker R: Random-effects model for meta-analysis of clinical trials: An update. Contemp Clin Trials 28:105-114, 2007 (Pubitemid 44937874)
20. Tang G, Shak S, Paik S, et al.: Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 127:133-142, 2011